Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies



Summary

Tumour-resident memory T cells (Trm) are critical for effective cancer immunotherapy, but their heterogeneity and specific roles remain unclear. Research reveals that different Trm subsets within tumors mediate distinct responses to anti-PD-1 and anti-CTLA-4 therapies. Specifically, some Trm subsets promote anti-PD-1 efficacy, while others are more important for anti-CTLA-4 responses. This suggests that the composition and function of Trm subsets within tumors can predict and potentially modulate the effectiveness of specific immunotherapies. Understanding these distinct roles allows for the development of more targeted strategies to enhance anti-tumor immunity and improve patient outcomes.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!